Novartis and a consortium of life sciences companies announced a collaboration to accelerate the development, manufacture and delivery of vaccines, diagnostics, and treatments for COVID-19 in response to the pandemic. The industry brings a range of assets, resources, and expertise needed to identify effective and scalable solutions to the pandemic that is affecting billions worldwide. Effects on health systems, economies, and livelihoods are significant, and effective response requires an unprecedented collaboration across government, academia, private sector, and philanthropy.

"We feel a deep shared responsibility to see if there are specific areas where collaboration across the life sciences industry and the Bill & Melinda Gates Foundation can accelerate solutions to this pandemic. In addition to the individual contributions companies are already making, collective action is critical to ensure any promising studies into vaccines, drugs, and diagnostics are quickly scaled to people around the world who are affected by this pandemic," co-chair of a consortium of life science companies headquartered across three continents, Vas Narasimhan, CEO of Novartis, said.

Trials of existing drugs, diagnostic tests, compounds, and investigational vaccines have begun around the world to identify interventions to slow or end the pandemic. Products that demonstrate efficacy will require clinical study, scale up of manufacturing, and distribution if proven effective. These are areas that the life sciences industry has extensive experience in managing for products that reach billions of people every day.

"We know that the private sector is where the technical skills from discovery to clinical trials to commercialization know-how sits. We look to harness that knowledge and experience, combine it where possible, to connect with national regulators and the World Health Organization to see if we can help flatten the curve of this pandemic and make sure the results reach everyone around the world, particularly those at highest risk and the poorest," Mark Suzman, chief executive officer of the Bill & Melinda Gates Foundation said.

Following a conference call with Gates Foundation leadership earlier this month, companies are working to identify concrete actions that will accelerate treatments, vaccines, and diagnostics to the field. As a first step, 15 companies have agreed to share their proprietary libraries of molecular compounds that already have some degree of safety and activity data – with the COVID-19 Therapeutics Accelerator launched by the Gates Foundation, Wellcome, and Mastercard two weeks ago to quickly screen them for potential against COVID-19. Successful hits would move rapidly into in vivo trials in as little as two months.

Companies participating in the collaboration include: BD, Boehringer Ingelheim, bioMerieux, Eisai, Eli Lilly, Gilead, GSK, J&J, Merck (MSD), Merck (Merck KGaA), Novartis, Pfizer, and Sanofi.

Register as Visitor to CPhI China 2020!

-----------------------------------------------------------------------
Editor's Note:

En-CPhI.CN is a vertical B2B online trade platform serving the pharmaceutical industry,

for any copyright disputes involved in the articles,

please email: Julia.Zhang@imsinoexpo.com to motify or remove the content.